TG Therapeutics
(NASDAQ) TGTX
TG Therapeutics Financials at a Glance
Market Cap
$8.21B
Revenue (TTM)
$700.35M
Net Income (TTM)
$461.90M
EPS (TTM)
$2.87
P/E Ratio
18.68
Dividend
$0.00
Beta (Volatility)
1.81 (High)
Dividend
$0.00
Beta (Volatility)
1.81 (High)
Price
$53.53
Volume
86,964
Open
$54.27
Price
$53.53
Volume
86,964
Open
$54.27
Previous Close
$53.53
Daily Range
$53.18 - $55.00
52-Week Range
$25.28 - $57.38
Estimated Earnings Date
Aug 3, 2026
Dividend
$0.00
Beta (Volatility)
1.81 (High)
Price
$53.53
Volume
86,964
Open
$54.27
Previous Close
$53.53
Daily Range
$53.18 - $55.00
52-Week Range
$25.28 - $57.38
Estimated Earnings Date
Aug 3, 2026
TGTX News
Best Biotech ETFs to Buy in 2026
TGTX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout TG Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
399
CEO
Michael Sean Weiss
Website
www.tgtherapeutics.comHeadquarters
Morrisville, NY 10014, US
TGTX Financials
Key Financial Metrics (TTM)
Gross Margin
83.04%
Operating Margin
21.35%
Net Income Margin
65.95%
Return on Equity
87.36%
Return on Capital
13.57%
Return on Assets
30.21%
Earnings Yield
5.35%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$8.21B
Shares Outstanding
153.08M
Volume
86.96K
Avg. Volume
2.23M
Financials (TTM)
Gross Profit
$581.60M
Operating Income
$149.50M
EBITDA
$150.19M
Operating Cash Flow
-$13.95M
Capital Expenditure
-$240.00K
Free Cash Flow
-$14.19M
Cash & ST Invst.
$514.43M
Total Debt
$753.56M
TG Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$204.92M
+69.6%
Gross Profit
$171.41M
+62.8%
Gross Margin
83.65%
N/A
Market Cap
$8.21B
N/A
Market Cap/Employee
$23.31M
N/A
Employees
352
N/A
Net Income
$19.78M
+290.8%
EBITDA
$28.11M
+128.9%
Quarterly Fundamentals
Total Cash
$514.43M
+86.2%
Total Debt
$753.56M
+197.0%
Accounts Receivable
$392.05M
+106.2%
Inventory
$129.03M
-18.2%
Long Term Debt
$751.74M
+197.6%
Short Term Debt
$1.82M
+63.3%
Return on Assets
30.21%
N/A
Return on Invested Capital
11.14%
N/A
Free Cash Flow
-$17.95M
+37.6%
Operating Cash Flow
-$17.89M
+37.7%